IL2RA and immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome: Treatment is mainly supportive for STAT5B deficiency and HSCT can be curative in IPEX and CD25 deficiency, while gene-editing will hopefully be a definitive therapeutic option in the future.